Download Library
Document Type
Double-masked, randomized, dose-response study of AR-13324 Ophthalmic Solution compared to latanoprost in patients with elevated intraocular pressure (Presented at American Glaucoma Society, 2014)
Presentations
Code of Business Conduct and Ethics
First in Human Clinical Study of a Novel Dual Mechanism Compound (AR-13324) for the Lowering of IOP in Glaucoma and Ocular Hypertension (Presented at Association for Research in Vision and Ophthalmology, 2013)
Presentations
Discovery and SAR of a Class of Ocularly-active Compounds Displaying a Dual Mechanism of Activity for the Treatment of Glaucoma (Presented at Association for Research in Vision and Ophthalmology, 2012)
Presentations
IOP-lowering efficacy and tolerability of AR-13324, a dual mechanism kinase inhibitor for the treatment of glaucoma (Presented at Association for Research in Vision and Ophthalmology, 2012)
Presentations
Page: FirstPrevious
4
= add file to Briefcase